News - Amgen, talimogene laherparepvec

Filter

Popular Filters

Retrospective analysis shows tumor shrinkage with Amgen's talimogene laherparepvec

Retrospective analysis shows tumor shrinkage with Amgen's talimogene laherparepvec

16-03-2014

Leading independent biotech firm Amgen says that findings from a pre-specified retrospective analysis…

AmgenBiotechnologyOncologyResearchtalimogene laherparepvec

Advanced melanoma collaboration for Amgen and Merck & Co

Advanced melanoma collaboration for Amgen and Merck & Co

05-02-2014

World leading independent biotech firm Amgen and US pharma giant Merck & Co have entered into an agreement…

AmgenBiotechnologyMerck & CoMK-3475OncologyResearchtalimogene laherparepvec

Favorable OS Ph III results with Amgen’s talimogene laherparepvec in melanoma patients

Favorable OS Ph III results with Amgen’s talimogene laherparepvec in melanoma patients

20-11-2013

USA-based Amgen has presented positive interim overall survival results from a pivotal Phase III trial…

AmgenBiotechnologyOncologyResearchtalimogene laherparepvec

Highlights from ASCO: Bayer's Nexavar; Novartis' Afinitor; and Amgen's talimogene laherparepvec

02-06-2013

The prestigious annual meeting of the American Society of Clinical Oncology (ASCO) kicked off this weekend…

AfinitorAmgenBayerBiotechnologyNexavarNovartisOncologyOnyx PharmaceuticalsPharmaceuticalResearchtalimogene laherparepvec

Amgen's talimogene laherparepvec Ph III trial in melanoma meets endpoint

21-03-2013

USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech company, has presented positive…

AmgenBiotechnologyOncologyResearchtalimogene laherparepvec

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top